17
Participants
Start Date
March 1, 2016
Primary Completion Date
September 30, 2020
Study Completion Date
September 30, 2020
ACY-1215
An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
Nab-paclitaxel
"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
Columbia Irving University Medical Center, New York
Collaborators (1)
Acetylon Pharmaceuticals Incorporated
INDUSTRY
National Cancer Institute (NCI)
NIH
Columbia University
OTHER